ALS News Today Home | ALS News Today
Nov 5, 2024 · Auttx gets ALS Network grant to develop new treatments for ALS. Biotech company Auttx has received a $125,000 grant to advance the development of new molecules that aim to restore normal RNA processing in people with amyotrophic lateral sclerosis (ALS), potentially leading to new treatments for ALS.
News Archives - ALS News Today
Auttx gets ALS Network grant to develop new treatments for ALS. Biotech company Auttx has received a $125,000 grant to advance the development of new molecules that aim to restore normal RNA processing in people with amyotrophic lateral sclerosis (ALS), potentially leading to new treatments for ALS.
Results of Phase 3 Trial of TUDCA in Slowing ALS ... - ALS News …
Nov 25, 2022 · An ongoing Phase 3 clinical trial in Europe is testing whether tauroursodeoxycholic acid, added to standard therapy, can slow disease progression and extend survival among people with amyotrophic lateral sclerosis (ALS).
FDA final approval decision on NurOwn for ALS due by year’s end
Jun 8, 2023 · A final decision by the U.S. Food and Drug Administration (FDA) on whether or not to approve NurOwn for amyotrophic lateral sclerosis (ALS) is now expected no later than Dec. 8.
ALS Study Results Clear Way to Test Utreloxastat on Patients | ALS …
Jan 30, 2023 · Utreloxastat (PTC857), an investigational therapy for people with amyotrophic lateral sclerosis (ALS), was safe, well tolerated, and displayed promising pharmacological properties in healthy people, according to a first-in-human Phase 1 study.
Phase 1 clinical trial of experimental ALS therapy ... - ALS News …
Aug 28, 2023 · Akava Therapeutics will soon launch a Phase 1 clinical trial to test AKV9, its investigational therapy for amyotrophic lateral sclerosis (ALS), in healthy people. The trial follows the clearance of Akava’s investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA).
MDA 2024: Planned Phase 3b trial aims to support ... - ALS News …
Mar 6, 2024 · A pivotal, Phase 3b clinical trial is planned to test the cell-based therapy NurOwn (debamestrocel) in people with amyotrophic lateral sclerosis (ALS), the treatment’s developer, Brainstorm Cell Therapeutics, announced.
S-oxprenolol granted orphan drug status by FDA as ALS treatment
Sep 6, 2024 · S-oxprenolol, an investigational therapy being developed by Actimed Therapeutics to treat muscle wasting in amyotrophic lateral sclerosis (ALS), has been granted orphan drug status in the U.S. That designation, awarded by the U.S. Food and Drug Administration, is given to therapies intended to treat rare diseases, like ALS, that affect fewer ...
ALS respiratory data now available to researchers worldwide
Oct 29, 2024 · A database integrating long-term respiratory data with natural history data from people with amyotrophic lateral sclerosis (ALS) has been made available to scientists globally, with the hopes of accelerating research and the discovery of new therapies.
Clene granted in-person FDA meeting on ALS therapy CNM-Au8
Sep 24, 2024 · Clene has been granted an in-person meeting with the U.S. Food and Drug Administration (FDA) — to be held before the end of November, according to the company — to discuss a potential accelerated approval of CNM-Au8 as a treatment for amyotrophic lateral sclerosis (ALS). Clene.